Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, announced that President and CEO Christopher J. Schaber, Ph.D., will deliver a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference scheduled for September 8-10, 2025. The on-demand presentation will be available beginning September 5 at 7 a.m. ET through the conference platform, with Soligenix management also participating in one-on-one meetings during the event.
The company's Specialized BioTherapeutics business segment is advancing HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this segment also include expansion of synthetic hypericin (SGX302) into psoriasis, first-in-class innate defense regulator technology dusquetide (SGX942) for inflammatory diseases including oral mucositis in head and neck cancer, and SGX945 in Behcet's Disease.
Soligenix's Public Health Solutions business segment includes development programs for RiVax®, the company's ricin toxin vaccine candidate, as well as vaccine programs targeting filoviruses such as Marburg and Ebola and CiVax™, the vaccine candidate for prevention of COVID-19 caused by SARS-CoV-2. The development of these vaccine programs incorporates the proprietary heat stabilization platform technology known as ThermoVax®.
This business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA). Investors can access the latest news and updates relating to SNGX in the company's newsroom at https://ibn.fm/SNGX. The full press release is available at https://ibn.fm/DkBRA.
The presentation at this major investment conference provides visibility for Soligenix's diverse pipeline addressing significant unmet medical needs in rare diseases and public health threats. The company's dual focus on specialized biotherapeutics and government-supported vaccine development represents a strategic approach to bringing novel treatments to market while leveraging public-private partnerships for infectious disease preparedness.
